145 related articles for article (PubMed ID: 21631271)
41. Prognostic impact of the activation status of the Akt/mTOR pathway in synovial sarcoma.
Setsu N; Kohashi K; Fushimi F; Endo M; Yamamoto H; Takahashi Y; Yamada Y; Ishii T; Yokoyama K; Iwamoto Y; Oda Y
Cancer; 2013 Oct; 119(19):3504-13. PubMed ID: 23861137
[TBL] [Abstract][Full Text] [Related]
42. [Plasmablastic lymphoma presenting clinical symptoms similar to plasmablastic myeloma].
Nakaya A; Nagate Y; Toda J; Yamashita Y; Hirose Y; Mori K; Shibayama H
Rinsho Ketsueki; 2023; 64(4):260-264. PubMed ID: 37121769
[TBL] [Abstract][Full Text] [Related]
43. Concurrent inhibition of PI3-kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1.
Zang C; Eucker J; Liu H; Müller A; Possinger K; Scholz CW
Cancer Lett; 2013 Oct; 339(2):288-97. PubMed ID: 23200668
[TBL] [Abstract][Full Text] [Related]
44. Expression of molecular markers associated with the mammalian target of rapamycin pathway in nonmetastatic renal cell carcinoma: Effect on prognostic outcomes following radical nephrectomy.
Nishikawa M; Miyake H; Harada K; Fujisawa M
Urol Oncol; 2014 Jan; 32(1):49.e15-21. PubMed ID: 24239474
[TBL] [Abstract][Full Text] [Related]
45. Concurrent classical Hodgkin lymphoma and plasmablastic lymphoma in a patient with chronic lymphocytic leukemia/small lymphocytic lymphoma treated with fludarabine: a dimorphic presentation of iatrogenic immunodeficiency-associated lymphoproliferative disorder with evidence suggestive of multiclonal transformability of B cells by Epstein-Barr virus.
Foo WC; Huang Q; Sebastian S; Hutchinson CB; Burchette J; Wang E
Hum Pathol; 2010 Dec; 41(12):1802-8. PubMed ID: 20869749
[TBL] [Abstract][Full Text] [Related]
46. Plasmablastic lymphoma and related disorders.
Hsi ED; Lorsbach RB; Fend F; Dogan A
Am J Clin Pathol; 2011 Aug; 136(2):183-94. PubMed ID: 21757592
[TBL] [Abstract][Full Text] [Related]
47. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers.
Zhou X; Tan M; Stone Hawthorne V; Klos KS; Lan KH; Yang Y; Yang W; Smith TL; Shi D; Yu D
Clin Cancer Res; 2004 Oct; 10(20):6779-88. PubMed ID: 15501954
[TBL] [Abstract][Full Text] [Related]
48. Alcohol consumption and decreased risk of non-Hodgkin lymphoma: role of mTOR dysfunction.
Hagner PR; Mazan-Mamczarz K; Dai B; Corl S; Zhao XF; Gartenhaus RB
Blood; 2009 May; 113(22):5526-35. PubMed ID: 19293424
[TBL] [Abstract][Full Text] [Related]
49. Role of mTOR signaling pathway in the pathogenesis of subependymal giant cell astrocytoma - A study of 28 cases.
Kumari K; Sharma MC; Kakkar A; Malgulwar PB; Pathak P; Suri V; Sarkar C; Chandra SP; Faruq M; Gupta RK; Saran RK
Neurol India; 2016; 64(5):988-94. PubMed ID: 27625244
[TBL] [Abstract][Full Text] [Related]
50. Expression and phosphorylation of eukaryotic translation initiation factor 4E binding protein 1 in B-cell lymphomas and reactive lymphoid tissues.
Kodali D; Rawal A; Ninan MJ; Patel MR; Mesa H; Knapp D; Schnitzer B; Kratzke RA; Gupta P
Arch Pathol Lab Med; 2011 Mar; 135(3):365-71. PubMed ID: 21366462
[TBL] [Abstract][Full Text] [Related]
51. Immunohistochemical Expression of mTOR in Multiple Myeloma: Retrospective Analysis of 31 Cases, a Clinicopathological Study.
Stockwin W; Johnson P; Vajpayee N
Ann Clin Lab Sci; 2016; 46(2):125-31. PubMed ID: 27098617
[TBL] [Abstract][Full Text] [Related]
52. Inhibition of mTOR signalling potentiates the effects of trichostatin A in human gastric cancer cell lines by promoting histone acetylation.
Sun DF; Zhang YJ; Tian XQ; Chen YX; Fang JY
Cell Biol Int; 2014 Jan; 38(1):50-63. PubMed ID: 24030871
[TBL] [Abstract][Full Text] [Related]
53. KHSV(-) EBV(-) post-transplant effusion lymphoma with plasmablastic features: variant of primary effusion lymphoma?
Lambe JS; Oble DA; Nandula SV; Sevilla DW; Colovai AI; Mansukhani M; Chari A; Murty VV; Alobeid B; Bhagat G
Hematol Oncol; 2009 Dec; 27(4):203-10. PubMed ID: 19337983
[TBL] [Abstract][Full Text] [Related]
54. PDK1 Mediates
Sambandam V; Frederick MJ; Shen L; Tong P; Rao X; Peng S; Singh R; Mazumdar T; Huang C; Li Q; Pickering CR; Myers JN; Wang J; Johnson FM
Clin Cancer Res; 2019 Jun; 25(11):3329-3340. PubMed ID: 30770351
[TBL] [Abstract][Full Text] [Related]
55. Large B-cell lymphomas with plasmablastic differentiation: a biological and therapeutic challenge.
Montes-Moreno S; Montalbán C; Piris MA
Leuk Lymphoma; 2012 Feb; 53(2):185-94. PubMed ID: 21812534
[TBL] [Abstract][Full Text] [Related]
56. Immunohistochemical and molecular analysis of PI3K/AKT/mTOR pathway in esophageal carcinoma.
Tasioudi KE; Sakellariou S; Levidou G; Theodorou D; Michalopoulos NV; Patsouris E; Korkolopoulou P; Saetta AA
APMIS; 2015 Aug; 123(8):639-47. PubMed ID: 25912437
[TBL] [Abstract][Full Text] [Related]
57. Intravascular large B-cell lymphoma: report of three cases and analysis of the mTOR pathway.
Shen Q; Duan X; Feng W; Nguyen N; Lapus A; Brown RE; Chen L
Int J Clin Exp Pathol; 2011; 4(8):782-90. PubMed ID: 22135726
[TBL] [Abstract][Full Text] [Related]
58. Human Herpesvirus Type 8-associated Large B-cell Lymphoma: A Nonserous Extracavitary Variant of Primary Effusion Lymphoma in an HIV-infected Man: A Case Report and Review of the Literature.
Foster WR; Bischin A; Dorer R; Aboulafia DM
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):311-21. PubMed ID: 27234438
[TBL] [Abstract][Full Text] [Related]
59. Plasmablastic Lymphoma: A Review of Clinicopathologic Features and Differential Diagnosis.
Harmon CM; Smith LB
Arch Pathol Lab Med; 2016 Oct; 140(10):1074-8. PubMed ID: 27684979
[TBL] [Abstract][Full Text] [Related]
60. Primary Gastric EBV-positive Diffuse Large B Cell Lymphoma (DLBCL) of the Elderly with Plasmablastic Differentiation.
Hu M; Trevino J; Yang L; Cao D; Liu X; Lai J
In Vivo; 2018; 32(2):413-417. PubMed ID: 29475930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
